LEVOSERT Intrauterine delivery system (IUS) Ref.[27903] Active ingredients: Levonorgestrel

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Gedeon Richter Plc., Gyömrői út 19-21., 1103 Budapest, Hungary

Product name and form

Levosert 20 microgram/24 hours Intrauterine Delivery System.

Pharmaceutical Form

Intrauterine delivery system (IUS).

The product consists of an inserter and levonorgestrel IUS, which is loaded at the tip of the inserter. Inserter components are an insertion tube, plunger, flange, body and slider. The device consists of a white or almost white hormone-elastomer core, mounted on a T-body and covered in opaque tubing, which regulates the release of levonorgestrel. The T-body has a loop at the end of the vertical stem and two horizontal arms at the other end. Removal threads are attached to the loop.

Qualitative and quantitative composition

The active substance is levonorgestrel (LNG).

The intrauterine delivery system contains 52 mg levonorgestrel. The initial release of levonorgestrel is approximately 20 micrograms per day. This rate decreases progressively to approximately 8.6 micrograms/day after 6 years. The average in vivo release rate of LNG is approximately 14.3 micrograms/day over a period of 6 years.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Levonorgestrel

The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest.

List of Excipients

Polydimethylsiloxane (PDMS) reservoir
Polydimethylsiloxane (PDMS) membrane
Low density polyethylene T-frame with 20-24% barium sulphate
Polypropylene thread
Copper phthalocyanine blue

Pack sizes and marketing

Levosert IUS with the inserter device is individually packed into a thermoformed blister (polyester) package with a peelable lid (TYVEK-Polyethylene).

Marketing authorization holder

Gedeon Richter Plc., Gyömrői út 19-21., 1103 Budapest, Hungary

Marketing authorization dates and numbers

PL 04854/0158

28/12/2012

Drugs

Drug Countries
LEVOSERT Austria, Ecuador, Estonia, Spain, Croatia, Ireland, Lithuania, Malta, New Zealand, Poland, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.